Traumatic brain injury (TBI) remains the most common cause of death and disability in children from the developed world. Evidenced-based guidelines have been published for children with severe TBI [1] , yet the practicality of these guidelines to inform clinical practice is limited by insufficient information. There are currently no level 1 recommendations and only four level 2 recommendations-three of which are therapies/maneuvers to avoid (immune-enhanced diet, steroids, and therapeutic hypothermia). The three largest randomized controlled trials (RCTs) for children with severe TBI have been performed to test the utility of early, therapeutic hypothermia and all have failed to demonstrate that the intervention positively impacted the primary outcomes of the studies [2-4]. Moreover, the remainder of the evidenced-based guideline consists of level 3 recommendations that "may be considered", largely because the studies informing these topics were (1) developed in a single center, (2) retrospective in nature with limited ability to obtain detailed follow-up, or (3) significantly limited in study design [5] . For adults with severe TBI, multicentered RCTs have almost universally failed to prove their primary hypothesis encompassing pharmacological therapies, therapeutic medical maneuvers, and surgical procedures [6] [7] [8] .
New paths for clinical care and research for TBI have emerged. The IMPACT study team, led by Dr. Maas and colleagues, combined more than a dozen clinical studies and determined that intercenter variations in outcomes were prominent and likely overwhelmed the therapeutic intervention under study [9] . Concurrently, Dr. Manley and colleagues embarked on studies to more thoroughly categorize the nature of the injuries by using biomarkers and neuroimaging [10] [11] [12] . These efforts-now comprising the Collaborative European Neurotrauma Effectiveness Research in TBI (CENTER-TBI) study and the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (or TRACK-TBI) study-are designed to better understand the entire spectrum of the disease (Table 1) .
For children, we chose another approach. Because of the lethality of TBI in children and the dearth of specific recommendations for treatments, we chose to compare the effectiveness of strategies for therapies that are (1) part of the evidenced-based guidelines and (2) in clinical use today. In preparation for our study that we call ADAPT (Approaches and Decisions for Acute Pediatric TBI), we found that the basic aspects of care that are outlined within the guidelines are applied in substantially varied ways in the leading TBI centers [13] . Therefore, we chose three TBI topics-intracranial hypertension therapies (cerebrospinal fluid diversion and hyperosmolar therapies), secondary insult detection/treatment [hyperventilation and hypoxia (based on brain tissue oxygen monitoring)], and metabolic support (nutrition administration and glucose control)-and developed hypotheses to answer some of these unanswered questions. To date, over 800 children [inclusion criteria: Glasgow Coma Scale score (GCS) ≤ 8, diagnosis of TBI, age < 18 years, placement of an intracranial pressure (ICP) monitor; exclusion criteria: pregnancy] have been consecutively enrolled at 49 clinical sites in the USA, Europe, South Africa, India, Australia, and New Zealand. Using statistical methods commonly employed within comparative effectiveness research including propensity scoring, we anticipate generating level 2 evidence for all of the primary hypotheses-more such recommendations than have been generated within the guidelines to date. Moreover, since this study design requires the understanding and control of many co-variates, we anticipate significant other information regarding other aspects of TBI care.
We believe ADAPT-which will be approximately five times larger than any previous study of this patient population-will serve to provide clinicians with contemporary evidence valuable for caring for children with severe TBI and future researchers with information regarding basic aspects of care that can be used to standardize patient care and allow future randomized trials to detect possible experimental signals. With the conclusion of our enrollment of 1000 children in the summer of 2016, we look forward to presenting our findings as rapidly as possible to the intensive care community. 
